

Caroline S Foo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5449185/publications.pdf>

Version: 2024-02-01

27
papers

3,420
citations

279487

23
h-index

525886

27
g-index

39
all docs

39
docs citations

39
times ranked

5738
citing authors

#	ARTICLE	IF	CITATIONS
1	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
2	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504
3	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021, 597, 97-102.	13.7	385
4	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , 2021, 373, 1109-1116.	6.0	262
5	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
6	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. <i>Science</i> , 2022, 375, 449-454.	6.0	108
7	The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. <i>Antiviral Research</i> , 2022, 198, 105253.	1.9	104
8	Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. <i>EBioMedicine</i> , 2021, 68, 103403.	2.7	102
9	Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. <i>Journal of Infectious Diseases</i> , 2021, 224, 749-753.	1.9	95
10	The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. <i>EBioMedicine</i> , 2021, 72, 103595.	2.7	91
11	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 719.	5.8	86
12	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. <i>Neurobiology of Disease</i> , 2014, 71, 345-358.	2.1	59
13	Structural studies of <i>Mycobacterium tuberculosis</i> DprE1 interacting with its inhibitors. <i>Drug Discovery Today</i> , 2017, 22, 526-533.	3.2	55
14	Arylvinyloxy piperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of <i>Mycobacterium tuberculosis</i> . <i>MBio</i> , 2018, 9, .	1.8	52
15	Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	49
16	Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	48
17	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. <i>Science Translational Medicine</i> , 2021, 13, eabi7826.	5.8	41
18	A highly potent antibody effective against SARS-CoV-2 variants of concern. <i>Cell Reports</i> , 2021, 37, 109814.	2.9	39

#	ARTICLE	IF	CITATIONS
19	New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in <i>Mycobacterium tuberculosis</i> . <i>PLoS Pathogens</i> , 2020, 16, e1008270.	2.1	38
20	Characterization of DprE1-Mediated Benzothiazinone Resistance in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6451-6459.	1.4	36
21	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. <i>Biochemical and Biophysical Research Communications</i> , 2021, 555, 134-139.	1.0	30
22	Oxidative Phosphorylation – an Update on a New, Essential Target Space for Drug Discovery in <i>Mycobacterium tuberculosis</i> . <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2339.	1.3	29
23	Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. <i>Antiviral Research</i> , 2021, 193, 105127.	1.9	27
24	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. <i>Molecular Therapy</i> , 2022, 30, 2968-2983.	3.7	20
25	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. <i>Antiviral Research</i> , 2022, 202, 105311.	1.9	8
26	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>iScience</i> , 2022, 25, 104705.	1.9	8
27	Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. <i>Microorganisms</i> , 2022, 10, 633.	1.6	3